Repligen’s strong growth and bioprocessing expansion position it for success. Find out why RGEN stock is a Buy, with a $175 ...

Shares of 908 Devices (NASDAQ:MASS) climbed ~71% in the premarket on Tuesday after Repligen (NASDAQ:RGEN) offered $70M in cash to acquire the company’s bioprocessing analytics portfolio. As part of ...

Proficio Capital Partners LLC purchased a new stake in shares of Repligen Co. (NASDAQ:RGEN – Free Report) in the fourth ...

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) in Q4 CY2024, but sales were flat year on year at $167.5 million. The company’s outlook for the full year was close to analysts’ ...

Equities researchers at Evercore ISI started coverage on shares of Repligen (NASDAQ:RGEN – Get Free Report) in a report ...

Learn more about whether Repligen Corporation or Bio-Techne Corporation is a better investment based on AAII's A+ Investor ...

Repligen Corporation (NASDAQ:RGEN), a leading pure-play bioprocess supplier with a market capitalization of $8.17 billion, has been navigating a complex market environment characterized by ...

Evercore ISI initiated coverage of Repligen (RGEN) with an In Line rating and $155 price target The firm sees the company as a high quality ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $181.67, a high estimate of $205.00, and a low estimate of $155.00. Highlighting a 7.12% decrease, the ...

Repligen Corporation RGEN reported fourth-quarter 2024 adjusted earnings per share of 44 cents, which beat the Zacks Consensus Estimate of 41 cents. The company had recorded adjusted earnings of ...

WALTHAM, Mass. and BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq: RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc ...

Repligen Corporation (NASDAQ:RGEN), a leading pure-play bioprocess supplier with a market capitalization of $8.17 billion, has been navigating a complex market environment characterized by ...